483
Original
Article
Non-Corresponding
Effects of an AngiotensinConverting
Enzyme
Inhibitor
on Cardiac
and
Vascular
Hypertrophy
in Spontaneously
Hypertensive
Rats
TOZAWA,
Masahiko
Shuichi
TAKISHITA
, Hiromi
MURATANI,
and
Koshiro
FUKIYAMA
Angiotensin-converting
enzyme inhibitors (ACEIs) may have different effects on cardiac hypertrophy than
on vascular hypertrophy. Arginine vasopressin (AVP) may promote cardiac hypertrophy. Our aims were (1)
to simultaneously
examine the chronic effects of ACEIs on hypertrophy of the heart and hypertrophy of
the coronary and renal interlobular arteries, and (2) to clarify the relation between AVP concentration
(AVPC) and cardiac hypertrophy. ACEI (delapril: 30 mg/kg/day) or vehicle (5% arabic gum) was administered in a preventive (4 to 28 weeks of age) or a therapeutic (12-24 weeks of age) protocol in spontaneously hypertensive rats. In both protocols, delapril produced a slight but significant decrease in systolic blood
pressure. In the therapeutic protocol, the weight of the left ventricle (mean±SE) was lower (p<0.05) in the
ACEI group (64±2 mg/100 g body weight) than in the control group (69±1 mg/100 g body weight). Plasma
renin activity was significantly higher in the ACEI group than in the control group in both the preventive (p
<0.01) and therapeutic (p<0.01) protocols. In the therapeutic protocol, AVPC was significantly (p<0.05)
lower in the ACEI group than in the control group. AVPC was significantly (p=0.02, r=0.46) correlated
with the weight of the left ventricle in the therapeutic protocol. For both protocols, no differences were
noted between the ACEI and control groups in the vascular hypertrophy of the coronary and renal interlobular arteries. We conclude that (1) the preventive or therapeutic effect of ACEIs on hypertrophy may not
be the same in the heart as in the coronary and renal arteries; and (2) AVP was significantly correlated
with the left ventricular weight. This indicates that AVP could play a role in the etiology of cardiac hypertrophy in SHR. (Hypertens Res 2000; 23: 483-490)
Key Words: hypertension,
vasopressin
cardiac
hypertrophy,
vascular
Chronic hypertension is associated with hypertrophy of
the cardiac muscle (1, 2) and the medial layer of arteries
and arterioles (3-5). Angiotensin-converting
enzyme inhibitors (ACEIs) have been shown to reduce cardiac
hypertrophy (1). ACEIs have been shown to reduce
Address
for Reprints:
Nishihara-cho,
Received
Nakagami-gun,
January
of Internal
Masahiko
Medicine,
Tozawa,
Okinawa
13, 2000; Accepted
renin-angiotensin
system,
arginine
vascular hypertrophy in the carotid, mesenteric, coronary,
and renal arteries of spontaneously hypertensive rats
Introduction
From the Third Department
hypertrophy,
University
M.D.,
Third
903-0215,
Japan.
in revised
form April
(SHR) (6), and to prevent development of atherosclerosis
in the large arteries by reducing vascular ACE activity in
monkeys on a high-cholesterol diet (7). In other studies
using SHR, ACEIs were found to simultaneously effective
on hypertrophy of the heart and hypertrophy of the
coronary, renal and mesenteric arteries (8, 9). Kett et al.
of the Ryukyus,
Department
10, 2000.
Okinawa,
of Internal
Japan.
Medicine,
University
of the
Ryukyus,
207
Uehara,
484
Hypertens Res Vol. 23, No. 5 (2000)
reported that ealapril treatment does not prevent vessel
wall hypertrophy of the renal interlobular and arcuate
arteries in SHR (10). And, in a regression study on SHR,
ACEIs were found to be effective on hypertrophy of
heart but not on vascular hypertrophy of the mesenteric
artery (11). The effect of ACEIs and the role of the
renin-angiotensin system in vascular hypertrophy remains
controversial. To test the hypothesis that the effect of
ACEIs on cardiac hypertrophy differs from that on vascular hypertrophy, we simultaneously examined the chronic
effects of delapril on hypertrophy of the heart and on
hypertrophy of the coronary and renal interlobular arteries in SHR using a preventive and a therapeutic protocol.
In addition, because arginine vasopressin (AVP) may
promote cardiac hypertrophy (12, 13) and, in an experimental study on left ventricular hypertrophy, chronic
treatment with ACE attenuated circulatory AVP (14), we
also assayed AVP concentration (AVPC) and examined
the relation between AVPC and left ventricular hypertrophy.
Methods
kit (Dainabot Ltd., Tokyo, Japan). AVPC was measured
by radioimmunoassay using an AVP-RIA kit (Mitsubishiyuka Ltd., Tokyo, Japan). PAC was measured by radioimmunoassay using an ALDOSTERONE
RIAKIT II kit
(Dainabot Ltd.).
Tissue Preparations
Owing the final week of each protocol, at the end of the
final week of each protocol, each rat was decapitated, and
the heart and kidney were dissected. The right ventricle
was removed from the heart and the left ventricle was
weighed. Immediately after tissue extraction, the left ventricle and kidney were fixed with phosphate buffered 10%
formalin solution. The left ventricles were cut into the
three parts (the upper, middle, and lower thirds), and
kidneys were cut sagittally into two parts. All these tissues were prepared routinely, and then 4-gm thick crosssections were stained with hematoxilin-eosin, periodic
acid-Schiff (PAS) and azan. Infiltration of lymphocytes
and fibrosis of the heart were classified as follows: 0,
none; 1, slight; 2, mild; or 3, moderate.
Animals
Cardiometry
Four-week-old male SHR (Charles River Inc., Atsugi,
Kanagawa, Japan) were fed standard rat chow and tap
water containing 1% NaCI ad libitum throughout the ex-
Coronal sections of the upper, middle and lower regions
were made from each ventricle. Free wall thickness, wall
area, lumen area, and perimeter of coronal-sectioned left
ventricles were measured by an image-analyzer (IBAS2000, Carl Zeiss Japan, Tokyo, Japan). Mean values of
the three regions (the upper, middle, and lower thirds) in
each were used for comparison.
periment. Systolic blood pressure (SBP) by the tail-cuff
method and body weight (BW) were measured weekly.
All experiments were performed in accordance with the
Guidelines for Animal Experimentation of the University
of the Ryukyus, and under the approval of the Animal
Care and Use Committee of the University of the
Ryukyus.
Experimental
Protocol
Delapril hydrochloride was administered by gavage from
the 4th to the 28th week of age in rats (n=13) in the preventive protocol and from the 12th to the 24th week of
age in rats (n = 8) in the therapeutic protocol. The daily
oral dose of delapril hydrochloride was 30 mg/kg . body
weight. Delapril hydrochloride (Takeda Chemical Industries, Ltd., Osaka, Japan) was suspended in 5% arabic
gum. Five percent arabic gum solution was given to control rats in both protocols (n=16 each). At the end of
each protocol, rats were killed by decapitation and trunk
blood was collected in an experimental tube with EDTA2Na. After the samples were centrifuged for 15 min at
3,000 rpm at 4°C, the plasma was collected and stored at
-20°C until use . Plasma renin activity (PRA), arginine
vasopressin concentration (AVPC), and plasma aldosterone concentration (PAC) were assayed. PRA was determined by radioimmunoassay using a RENIN RIABEAD
Evaluation of Vascular Thickness
Thickening of the coronary and renal interlobular arteries
were graded as normal, mild or moderate (Fig. 1). Histologic findings of coronary and interlobular arteries were
graded as follows: Stage 0, no thickened vessels observed;
Stage 1, one or two vessels in the mild grade and the
moderate grade are observed; or Stage 2, two or three
vessels in the mild grade and three or four vessels in the
moderate grade are observed. The stage of each sample
was determined according to the findingsof three sections
from the left ventricles and one section from the kidney.
Three transverse sections were obtained, one each from
the upper, middle, and lower thirds of the left ventricle.
One central sagittal section was obtained from each kidney. The stages of all samples were determined by a single examiner (AS). For quantitative evaluation of the
vascular thickening, the cross-sectional area (CSA) of a
vessel wall was calculated as the CSA of the whole vessel
minus the CSA of the lumen.
Tozawa
et al:
ACEI
and
Cardiac
and
Vascular
Hypertrophy
485
Fig. 1. Three grades of vascular thickening of the coronary arteries, normal (a), mild (b), and moderate (c), and of the renal interlobular arteries, normal (d), mild (e), and moderate (f). Scale bars equal 100 tim. According to these grades, the
histologic findings of the coronary and interlobular arteries are classified into three stages (described in the text).
in
Statistics
Values are expressed as the means ± SE. The statistical
significance of blood pressure (ACEI group vs. control
group) was tested by analysis of variance and Bonferoni ttest. The statistical significance of cardiac measurement
and CSA of vessels (ACEI group vs. control group) was
tested by Student's unpaired t-test. The statistical significance of vascular thickening as determined by histological stage (ACEI group vs. control group) was tested by
Mann-Whitney U test. P values less than 0.05 were considered to indicate statistical significance.
Results
Body Weights and Systolic Blood Pressure
In the preventive protocol, BW in the final week was lower in the ACEI group than in the control group (p<
0.05). This difference was absent in the therapeutic protocol (Table 1). In both protocols, SBP in the final week
was lower in the ACEI group than in the control group (p
<0.05).
the
group.
creased
ACEI
Cardiometry
Throughout the study, SBP in the preventive protocol
was lower in the ACEI group than in the control group
(Fig. 2). Until week 11, in the therapeutic protocol, SBP
was
similar
ACEI
group.
was
to
that
introduced
in
the
, and
control
SBP
de-
of the Left Ventricle
In the preventive protocol, no intergroup differences in
left ventricular (LV) weight were observed. In the therapeutic protocol, the LV weight was lower in the ACEI
group (64±2 mg/100 g body weight) than in the control
group (69± 1 mg/100 g body weight, p<0.05). In the preventive protocol, the LV wall area was less in the ACEI
group (56 ± 1 mm2) than in the control group (61±1
mm2, p<0.05). No such difference was observed in the
therapeutic protocol. In both protocols, no intergroup differences were noted in LV wall thickness. In the preventive protocol, the LV perimeter was smaller in the ACEI
group (30±0.4 mm) than in the control group (33±0.3
mm, p<0.05).
No such intergroup
difference was
observed in the therapeutic protocol. In both protocols,
the LV lumen area was less (p<0.05) in the ACEI group
than in the control group.
Histological
Course of Systolic Blood Pressure
group
At week 11,
in the ACEI
Change of the Heart
In the preventive protocol, the mean grade ± SE of lymphocyte infiltration was 1.3±0.1 in the ACEI group and
1.1 ± 0.1 in the control group (p = 0.24, ACEI vs. control). In this protocol, the mean grade of fibrosis was 2.2
Hypertens Res Vol. 23, No. 5 (2000)
486
Fig. 2. Weekly systolic blood pressure of spontaneously hypertensive rats. The left panel shows the preventive effects of the
angiotensin-converting enzyme inhibitor (ACEI) on blood pressure. The right panel shows the therapeutic effect of the
ACEI on blood pressure in spontaneously hypertensive rats. Values are means ± SE.
Table
1.
Final
Week
Body
Weight
and
Systolic
Blood
Pressure
in the
of the Experiment
Radioimmunoassay
PRA was significantly higher in the ACEI group than in
the control group in both the preventive (p<0.01) and
therapeutic (p<0.01) protocols (Table 3). AVPC in the
preventive protocol was similar in both groups in the
therapeutic protocol. In the therapeutic protocol, AVPC
was significantly (p<0.05) lower in the ACEI group than
in the control group. In the therapeutic protocol, PAC
was similar between the two groups. In the preventive
protocol, PAC was significantly (p<0.05) lower in the
ACEI group than in the control group. In the preventive
± 0.1 in the ACEI
group and 2.1 ± 0.1 in the control
group (p0.84).
=
In the therapeutic protocol, the mean
grade of lymphocyte infiltration was 1.0 ± 0 in the ACEI
group and 0.9 ± 0.1 in the control group (p = 0.49). In the
therapeutic protocol, the mean grade of fibrosis was 1.3±
0.1 in the ACEI and 1.6 ± 0.1 in the control group (p =
0.26).
Vascular Thickening
In both protocols, no intergroup
differences were
observed in the vasculature composition (intima, media,
fibrous tissue). In addition, no intergroup differences
were noted in the grade of vascular thickening in the
coronary or renal interlobular arteries (Table 2). And no
significant intergroup differences were noted in the CSA
of the coronary or renal interlobular arteries (Fig. 4).
protocol, no significant correlation existed between LV
weight and either PRA (p=0.66) or AVPC (p=0.17). In
the therapeutic protocol, a negative correlation (p=0.02,
r= -0.47) was observed between PRA and LV weight,
and a positive correlation (p=0.02, r=0.46) was observed
between AVPC and LV weight (Fig. 5).
Discussion
Delapril is a nonsulfhydryl ACEI (15) and potently inhibits ACE in plasma, aorta, kidney, lung and brain in
SHR (16), and is used in the clinical treatment of hypertension (17). In the present study, circulatory PRA was
higher in the ACEI group than in the control group. This
finding indicated that the renin angiotensin system was inhibited and that plasma renin increased through positive
feedback following blockade of angiotensin II generation
(18) . Delapril produced a slight but significant decline in
SBP. Cardiac dilation was reversed, and cardiac weight
was decreased. Vascular hypertrophy continued in the
coronary and interlobular arteries. These results suggest
that delapril does exert both preventive and therapeutic
Tozawa
Table
2.
Effect
of ACEI
on Vascular
Thickening
in Coronary
and
et al: ACEI and Cardiac
Renal
Interlobular
and Vascular
Hypertrophy
487
Arteries
effects on hypertrophy of the heart, but that it does not
have the corresponding effects on hypertrophy of the
coronary and renal arteries. In addition, ACEI treatment
reduced circulatory AVPC. AVPC was significantly correlated with the left ventricular weight. AVP could thus
play a role in the etiology of cardiac hypertrophy in SHR.
We used 1% NaCI as drinking water to expand the intravascular volume to make the hypertension relatively
refractory to the administration of ACEI. The difference
of blood pressure between the control and ACEI groups
was significant although small. In this experiment, we
were able to test the effect of delapril on the pressure-independent mechanisms of tissue hypertrophy more extensively than on the pressure-dependent mechanisms.
In both the preventive and therapeutic protocols, delapril did not change the left ventricular wall thickness,
but it did improve or regress the cardiac lumen area (Fig.
3). ACEIs have been shown to be more effective at improving left ventricular dilation of the lumen, i.e. , eccentric hypertrophy (1), than thickening of the left ventricular wall, i.e. , concentric hypertrophy (1). Eccentric hypertrophy is volume-dependent (1), and aldosterone may
Fig. 3. Bar graphs show data from cardiometry of the left
ventricle in the preventive protocol (Px), and the therapeutic protocol (Tx), with angiotensin converting enzyme inhibitor (ACEI) and control vehicle (C) in spontaneously
hypertensive rats. The weight, wall area, wall thickness,
perimeter, and lumen area of the left ventricle are shown.
Note that the left ventricular weights are shown as a ratio:
weight of left ventricle/body weight (mg/100 g body weight).
NS, not significant. *p<0.05, vs. control group. Values
are means ± SE.
play a role in developing this type of hypertrophy. Aldosterone production is decreased during ACE inhibition by
ACEI (19-21), and ACEI might ameliorate volume overload by reducing both aldosterone production and left
ventricular dilation. In the preventive protocol, PAC was
lower in the ACEI group than in the control group,
which apparently supports this hypothesis.
The effect of delapril on cardiac hypertrophy was consistent with that observed in experiments using other
types of ACEIs (8, 9, 11, 22-24). Cardiac hypertrophy in
hypertension is thought to be induced by both the hypertension itself and various humoral circulating growth factors. One of these growth factors, tissue angiotensin II is
known to be an endogenous growth factor (25, 26), and
thus may account for be implicated in the pathophysiolo-
488
Table
Hypertens Res Vol. 23, No. 5 (2000)
3.
Plasma
Renin
Activity,
Arginine
Vasopressin,
and Plasma
Fig. 4. Bar graphs show data obtained from digitizer
analysis of the coronary arteries (upper panel) and renal
interlobular arteries (lower panel) of the preventive protocol (Px) and therapeutic protocol (Tx), with angiotensinconverting enzyme inhibitor (ACEI) and control vehicle
(C) in spontaneously hypertensive rats. CSA, wall crosssectional area; NS, not significant. Values are means ±SE.
gy of left ventricular hypertrophy (22). Suppression of the
renin-angiotensin system could improve cardiac hypertrophy.
ACEI did not alter vascular hypertrophy in the present
study, a finding in contradiction to previous reports that
have shown a preventive effect of ACEIs on vascular
hypertrophy in the cerebral (27), carotid (6), mesenteric
(6, 8, 9, I1), coronary (6, 8, 9) and renal (6, 8, 9) arteries. Li et al. (8) and Clozel et al. (6, 8, 27) used cilazapril
as an ACE inhibitor. Delapril and cilazapril are prodrugs,
and the IC50 values (the concentration of drugs required
for the 50% inhibition of rabbit lung ACE) of CV-3317COOH (the active form of delapril)lcaptopril and Ro 31-
Aldosterone
Concentration
Fig. 5. Relation between plasma renin activity (PRA) or
arginine vasopressin concentration (AVPC) and left ventricular weight in the therapeutic protocol. ACEI, angiotensin-converting enzyme inhibitor; LVW, left ventricular
weight; BW, body weight.
3113 (the active form of cilazapril)lcaptopril were 4.0X
108 M15.8X 10-v M (16) and 1.93 nM/6.93 nM (28), respectively. The potency measured by ICS0values for CV3317-000H over Ro 31-3113 was 4-fold. The dose (30
mg/kg/day) and potency of delapril in the present study
were greater than those of cilazapril (10 mg/kg/day) in
previous studies (6, 27). In these prior studies, cilazapril
was administered for 19 weeks, which was longer than the
12 weeks of our therapeutic protocol but shorter than the
Tozawa et al: ACEI and Cardiac
24 weeks of our preventive protocol. Based on these
facts, the discrepancy in the results of vascular hypertrophy between our experiments and previous studies (6, 27)
may not be related to the dose, character or duration of
ACEI administration.
In the vasculature and myocardium, hypertension and
the pressure-independent mechanisms are considered
mechanisms of hypertrophy (29). The pressure-dependent
mechanism that includes stretch or wall stress in pressure
overload may stimulate hypertrophy of the heart (30) and
blood vessels (31). In the studies of Li et al. (8) and
Sharifi et al. (9), ACEI simultaneously reduced cardiac
and vascular hypertrophy in SHR. In these experiments,
the blood pressure reduction (>60 mmHg) was larger
than that seen here (<_20 mmHg). Thus the benefit of
pressure reduction in the present study was smaller than
that seen in previous studies. We observed a reduction
only in cardiac hypertrophy but not in vascular hypertrophy. These findings support the notion that the pressuredependent mechanism is more dominant in the hypertrophy of these vessels than in that of the heart, or that the
effects of ACEI on the pressure-independent mechanisms
of cardiac and vascular hypertrophy may not be the same.
Kett et al. (10) reported that ACEI treatment did not
prevent vessel wall hypertrophy in renal interlobular and
arcuate arteries in SHR. In their study, ACEI reduced
blood pressure substantially (>50 mmHg), although they
did not include the heart and coronary arteries. Together,
our data and the findings of Kett et al. (10) - which are
at least partially consistent - suggest that the renin-angiotensin system may make only a limited contribution to
vessel wall hypertrophy of the renal arteries in SHR.
AVP has been shown to increase the rate of protein
synthesis in neonatal rat cardiomyocytes (12) and isolated
perfused adult rat hearts via the V1 receptor (13). This
increase indicates that AVP may promote cardiac hypertrophy. Chronic blockade of the renin-angiotensin system
by ACEI (ramipril) significantly attenuated circulating
and central vasopressin in rats with LVH due to aortic
banding (14). In our study, AVPC was significantlysuppressed in the therapeutic protocol group following ACEI
treatment. And AVPC was significantly correlated with
LV weight in the protocol group. Given its antidiuretic,
vasoconstrictive, and growth-promoting effects, vasopressin may participate in the cardiovascular alterations in LV
hypertrophy (14).
In summary, we investigated the preventive and therapeutic effects of ACEI on hypertrophy of the heart and
coronary and renal interlobular arteries. The circulatory
renin-angiotensin system seemed to be inhibited. In our
study, the BP reduction was mild, and cardiac mass and
volume regressed. Hypertrophy of the coronary and renal
interlobular arteries did not change. In the therapeutic
protocol, ACEI treatment was able to reduce AVPC and
cardiac hypertrophy in SHR. AVPC was correlated with
the
left
effects
ventricular
of ACEI
cardiac
weight.
on
hypertrophy
and
renal
vascular
play
a role
in the
and Vascular
the
In
tissue
may
conclusion,
the
renin-angiotensin
differ
from
those
In
addition,
hypertrophy.
etiology
Hypertrophy
of cardiac
hypertrophy
489
inhibitory
system
in
in
coronary
AVP
may
in SHR.
Acknowledgements
We thank Akio Shino, Ph.D., of the Biology Research Laboratories of Takeda Chemical Industries, Ltd., and Ms. Naomi
Kaneda, Ms. Chiho Iseki and Ms. Rijiko Matayoshi for their
excellent technical assistance.
References
1
2
3
4
5
6
7.
8
9
10.
11
12.
Frohlich ED, Apstein C, Chobanian AV, et al: The
heart in hypertension. N Engl J Med 1992; 327: 9981008.
Devereux RB, Roman MJ: Left ventricular hypertrophy
in hypertension: stimuli, patterns, and consequences.
Hypertens Res 1999; 22: 1-9.
Wolinsky H: Response of the rat aortic media to hypertension: morphological and chemical studies. Circ Res
1970; 26: 507-522.
Folkow B, Hallback M, Lundgren Y, Weiss L: Background of increased flow resistance and vascular reactivity in spontaneously hypertensive rats. Acta Physiol
Scand 1970; 80: 93-106.
Folkow B : Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 437-504.
Clozel JP, Kuhn H, Hefti F: Decreases of vascular
hypertrophy in four different types of arteries in spontaneously hypertensive rats. Am J Med 1989; 87 (Suppl
6B): 92S-95S.
Miyazaki M, Takai S: Antiatherosclerotic effect of
alacepril, an angiotensin-converting enzyme inhibitor, in
monkeys fed a high-cholesterol diet. Hypertens Res 1999;
22: 49-54.
Li JS, Schiffrin EL: Effect of calcium channel blockade
or angiotensin-converting enzyme inhibition on structure
of coronary, renal, and other small arteries in spontaneously hypertensive rats. J Cardiovasc Pharmacol
1996; 28: 68-74.
Sharifi AM, Li JS, Endemann D, Schiffrin EL: Effects of
enalapril and amlodipine on small-artery structure and
composition, and on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 1998; 18: 457466.
Kett MM, Alcorn D, Bertram JF, Anderson WP: Enalapril does not prevent renal arterial hypertrophy in
spontaneously hypertensive rats. Hypertension 1995; 25:
335-342.
Linz W, Gohlke P, Unger T, Scholkens BA: Experimental evidence for effects of ramipril on cardiac
and vascular hypertrophy beyond blood pressure reduction. Arch Ma! Coeur Vaiss 1995; 88 (Spec No. 2): 31-34.
Xu Y, Hopfner RL, McNeill JR, Gopalakrishnan V:
Vasopressin accelerates protein synthesis in neonatal rat
490
13.
14.
15.
16.
17.
18.
19.
20.
21.
HypertensRes Vol. 23, No. 5 (2000)
cardiomyocytes. Mol Cell Biochem 1999;195: 183-190.
Fukuzawa J, Haneda T, Kikuchi K: Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell
Biochem 1999;195: 93-98.
Muders F, Elsner D, Schunkert H, Riegger GA, Palkovits M: Central vasopressin is modulated by chronic
blockade of the renin-angiotensin system in experimental
left ventricular hypertrophy. Am J Hypertens 1999; 12:
311-314.
Miyake A, Itoh K, Oka Y: Design and synthesis of N[N-[(S)]-L-alanyl]-N-(indan-2 yl) glycine (CV-3317), a
new, potent angiotensin converting enzyme inhibitor.
Chem Pharm Bull (Tokyo) 1986; 34: 2852-2858.
Inada Y, Terashita Z, Imura Y, Tanabe M, Nishikawa
K, Kikuchi S: Inhibition of angiotensin converting enzyme by CV-3317, a non-sulfhydryl compound. Jpn J
Pharmacol 1986; 42: 99-108.
Shionori H, Yamada G, Ikeda A, Ohta T, Miyajima E,
Kaneko Y: Pharmacokinetics and depressor effect of
delapril in patients with essential hypertension. Clin
Pharmacol Ther 1987; 40: 74-79.
Nussberger J, Brunner DB, Waeber B, Biollaz J, Brunner HR: Lack of angiotensin I accumulation after converting enzyme blockade by enalapril or lisinopril in
man. Clin Sci 1987; 72: 387-389.
Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA,
McKinsry DN: Clinical experience with blockade of the
renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,255 or captopril) in hypertensive patients. Prog Cardiovasc Dis 1978; 21: 195-206.
Brunner HR, Gavras H, Waeber B, et al: Oral angiotensin-converting enzyme inhibitor in long term treatment of hypertensive patients. Ann Intern Med 1979; 90:
19-23.
Atlas SA, Case DB, Sealey JE, Laragh JH, Mckinstry
DN: Interruption of the renin angiotensin system in
hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
and natriuresis. Hypertension 1979; 1: 274-280.
Nagano M, Higaki J, Mikami H, et al: Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 1991; 9: 595-599.
Julius S, Li Y, Brant D, Krause L, Taylor D: Quinapril,
an angiotensin converting enzyme inhibitor, prevents
cardiac hypertrophy during episodic hypertension. Hypertension 1991; 17: 1161-1166.
Benetos A, Albaladejo P, Levy BI, Safar ME: Acute
and long-term effects of angiotensin converting enzyme
inhibition on larger arteries and cardiac hypertrophy:
mechanical and structural parameters. J Hypertens 1991;
12 (Suppl 4): S21-S29.
Jackson TR, Blair LAC, Marshall J, Goedert M, Hanley
MR: The mas oncogene encodes an angiotensin receptor. Nature 1988; 335: 437-440.
Lever AF: Slow developing pressor effect of angiotensin
II and vascular structure. J Hypertens 1993; 11 (Suppl
3): S27-S28.
Clozel JP, Kuhn H, Hefti F: Effects of cilazapril on the
cerebral circulation in spontaneously hypertensive rats.
Hypertension 1989;14: 645-651.
Natoff IL, Nixon JS, Francis RJ, et al: Biological properties of the angiotensin converting enzyme inhibitor
cilazapril. J Cardiovasc Pharmacol 1985; 7: 569-580.
Bianchi G, Ferrari P, Barber BR: Lessons from experimental genetic hypertension. in Laragh JH, Brenner
BM (eds): Hypertension; Pathophysiology, Diagnosis,
and Management. New York, Raven Press, 1990, pp
914-915.
Anversa P, Ricci R, Olivetti G: Quantitative structural
analysis of the myocardium during physiologic growth
and induced cardiac hypertrophy: a review. J Am Coil
Cardiol 1986; 7: 1140-1149.
Dzau VJ: The role of mechanical and humoral factors in
growth regulation of vascular smooth muscle and cardiac
myocytes. Curr Opin Nephrol Hypertens 1993; 2: 27-32.